VIDEO: PALADIN, NEW DAY studies investigate Iluvien in patients with DME

ByMike Padilla

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WAIKOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2022, Mike Padilla, vice president of marketing at Alimera Sciences, discusses several trials.

Padilla highlights the NEW DAY study, comparing Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) as baseline therapy with aflibercept in patients with diabetic macular edema.

Published by:

Sources/Disclosures

Collapse

Source:

Mike Padilla

Read more about

fluocinolone acetonide

diabetic macular edema

ophthalmic business

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment